Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 in Primary Immune Thrombocytopenia (Phase 2/3 seamless)
CTR20200787Phase 3Completed
- Sponsor
- Harbour BioMed
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of batoclimab in immune thrombocytopenia (ITP), sponsored by Harbour BioMed. Started Jun 2020; status: completed.
02
Drugs
batoclimab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20200787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200787.